Equities Analysts Issue Forecasts for Edwards Lifesciences Co.’s FY2024 Earnings (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Zacks Research dropped their FY2024 earnings per share estimates for shares of Edwards Lifesciences in a research note issued to investors on Wednesday, August 14th. Zacks Research analyst U. Biswas now anticipates that the medical research company will earn $2.68 per share for the year, down from their prior estimate of $2.77. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.71 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q3 2025 earnings at $0.70 EPS, Q4 2025 earnings at $0.69 EPS and FY2025 earnings at $2.78 EPS.

Several other research firms have also issued reports on EW. Deutsche Bank Aktiengesellschaft cut their price target on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, July 25th. Canaccord Genuity Group reduced their price target on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. Daiwa America raised Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, July 31st. Piper Sandler dropped their price objective on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research note on Thursday, July 25th. Finally, The Goldman Sachs Group decreased their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Fourteen analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $82.10.

Edwards Lifesciences Price Performance

EW stock opened at $69.36 on Monday. The firm has a market cap of $41.80 billion, a P/E ratio of 29.90, a P/E/G ratio of 2.57 and a beta of 1.11. The firm’s fifty day moving average is $80.05 and its 200 day moving average is $85.70. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter in the previous year, the company posted $0.66 EPS. Edwards Lifesciences’s quarterly revenue was up 6.7% compared to the same quarter last year.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently made changes to their positions in the business. Park Avenue Securities LLC increased its position in Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after buying an additional 108 shares in the last quarter. City State Bank increased its holdings in Edwards Lifesciences by 16.5% in the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after acquiring an additional 130 shares in the last quarter. Chapin Davis Inc. raised its stake in Edwards Lifesciences by 1.7% during the 1st quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after acquiring an additional 140 shares during the period. Johnson Financial Group Inc. lifted its holdings in Edwards Lifesciences by 23.0% during the fourth quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 144 shares in the last quarter. Finally, Valley National Advisers Inc. boosted its position in shares of Edwards Lifesciences by 6.0% in the first quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after purchasing an additional 152 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 8,617 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $87.68, for a total transaction of $755,538.56. Following the sale, the chief executive officer now owns 68,218 shares in the company, valued at $5,981,354.24. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 8,617 shares of the stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $87.68, for a total value of $755,538.56. Following the completion of the transaction, the chief executive officer now directly owns 68,218 shares in the company, valued at approximately $5,981,354.24. The disclosure for this sale can be found here. Insiders have sold a total of 24,867 shares of company stock valued at $2,077,526 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.